# Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma

> **NCT01988493** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 117 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Tepotinib 300 mg
- **DRUG:** Tepotinib 500 mg
- **DRUG:** Tepotinib 1000 mg
- **DRUG:** Tepotinib
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT01988493
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-06
- **Primary completion:** 2018-02-05
- **Final completion:** 2020-12-03
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2022-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01988493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01988493, "Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01988493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*